About Antibody Drug Conjugates
Combining the selectivity of monoclonal antibodies with potent
cytotoxic agents
Antibody drug conjugate (ADC) technology leverages the selectivity
of monoclonal antibodies (MAbs) to offer novel possibilities to cancer
patients.1 This approach has been utilized in the
management of select hematologic malignancies and solid tumors.1,2
ADCs can be an effective and targeted vehicle designed to deliver
potent cytotoxic agents directly to tumor cells through selective
antibody binding.3
ADCs are a rational vehicle to exploit the internalization of
monoclonal antibodies for the delivery of a potent cytotoxic agent
inside target cells.3,4
This technology may be applied as foundational ADC therapy or as a
potential complement to existing treatment approaches.1
Genentech is currently investigating the potential of using an ADC
with other agents such as traditional monoclonal
antibodies, including PD-L1
inhibitors, small
molecules, and T-cell
bispecific antibodies.5,6